Daiichi Sankyo's small China acquisition should aid portfolio development
This article was originally published in Scrip
Daiichi Sankyo has reached an agreement to acquire a small trading company in China in a move designed to ease the importation and sale of its products, including those from its Indian subsidiary Ranbaxy.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.